Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pancreas Clear all
Completed Phase 3 Interventional Results available

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

NCT03691779
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Not applicable Interventional Results available

Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator

NCT01945060
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
heart rate Control to Range System (hrCTR) using DiAs Platform, DiAs Control-to-Range System not informed for heart rate
Device · Other
Lead sponsor
Marc Breton
Other
Eligibility
12 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Immunochemoradiotherapy in Patients With Pancreatic Cancer

NCT01342224
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma
Interventions
tadalafil and vaccination
Biological
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Not applicable Interventional Results available

Stereotactic Radiation to Decrease Pancreatic Secretions

NCT01656486
View directory record Official record
Conditions
Pancreatic Fistulae
Interventions
Stereotactic Radiation
Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

Capecitabine and Temozolomide for Neuroendocrine Cancers

NCT00869050
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Capecitabine, Temozolomide
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer

NCT00331682
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
alvocidib, docetaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Jul 23, 2026, 6:24 AM EDT
Recruiting No phase listed Observational

Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

NCT05746182
View directory record Official record
Conditions
Pancreatic Neuroendocrine Neoplasm
Interventions
Hereditary Cancer Panel
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
300 participants
Timeline
2023 – 2026
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Recruiting Phase 2 Interventional

Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus

NCT06729996
View directory record Official record
Conditions
Pancreatitis, Chronic, Pancreatitis, Acute, Diabetes Mellitus
Interventions
Pioglitazone (PIO), Empagliflozin (EMPA)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer

NCT03848182
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, TT vaccine booster
Drug · Biological
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated No phase listed Observational Results available

Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution

NCT02038803
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
TOBIpodhaler
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Not applicable Interventional

MPC Versus PID for Closed Loop Insulin Delivery

NCT02438670
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
PID control algorithm, MPC control algorithm
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer

NCT02101580
View directory record Official record
Conditions
Advanced Pancreatic Cancer
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

NCT06208124
View directory record Official record
Conditions
Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
Interventions
IMM-6-415
Drug
Lead sponsor
Immuneering Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Scottsdale, Arizona • Duarte, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

NCT03140527
View directory record Official record
Conditions
Healthy Volunteer, Cystic Fibrosis
Interventions
PTI-801, Placebo, PTI-808
Drug
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
33
States / cities
Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants

NCT07349394
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VNZ/TEZ/D-IVA, Rosuvastatin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Not yet recruiting Not applicable Interventional

INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study

NCT07671937
View directory record Official record
Conditions
Breast Cancer, Corpus Uteri Cancer, Ovary Cancer, Pancreas Cancer, Other Female Genital Malignant Neoplasms
Interventions
INSPIRE (INtegrating Systematic PatIent-Reported Evaluations), Capture of patient-reported outcomes, Enhanced Clinician Awareness
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
2,748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Birmingham, Alabama • Los Angeles, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 3 Interventional

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

NCT00031837
View directory record Official record
Conditions
Pancreatic Cancer, Thromboembolism
Interventions
dalteparin, gemcitabine hydrochloride, quality-of-life assessment
Drug · Procedure
Lead sponsor
Gary Morrow
Other
Eligibility
18 Years to 120 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
13
States / cities
Mobile, Alabama • Denver, Colorado • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jul 23, 2026, 6:24 AM EDT
Active, not recruiting Phase 2 Interventional

9-ING-41 in Patients With Advanced Cancers

NCT03678883
View directory record Official record
Conditions
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
Interventions
9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan
Drug
Lead sponsor
Actuate Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 2 Interventional

ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas

NCT00005594
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ISIS 2503
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Birmingham, Alabama • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 3, 2011 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Not applicable Interventional Results available

"Answers in Hours" A Randomized Controlled Trial Using Microbiome Metagenomics for Bile Duct Cultures

NCT05523154
View directory record Official record
Conditions
Benign Pancreatic Neoplasm, Malignant Pancreatic Neoplasm
Interventions
Biospecimen Collection, Laboratory Procedure, Nanopore Sequencing
Procedure · Other · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Jul 23, 2026, 6:24 AM EDT
Completed No phase listed Observational

Pediatric Longitudinal Cohort Study of Chronic Pancreatitis

NCT03672422
View directory record Official record
Conditions
Pancreatitis, Chronic, Pancreatitis, Acute
Interventions
Blood sample, Patient questionnaires, Saliva sample, Urine sample
Diagnostic Test · Behavioral
Lead sponsor
Aliye Uc
Other
Eligibility
0 Years to 17 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
18
States / cities
Beverly Hills, California • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 2 Interventional Results available

First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors

NCT03681951
View directory record Official record
Conditions
Neoplasms, Pancreatic
Interventions
GSK3145095, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Indianapolis, Indiana • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Jul 23, 2026, 6:24 AM EDT
Active, not recruiting Phase 2 Interventional

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

NCT06812988
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Brivekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 35 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Columbus, Georgia • Farmington Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

Artificial Pancreas Control System in an Inpatient Setting

NCT01552603
View directory record Official record
Conditions
Type I Diabetes Mellitus
Interventions
Artificial Pancreas Control Software
Device
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Jul 23, 2026, 6:24 AM EDT